Patent application EP15382590A (EP), filed 2015-11-27
Publication number: EP3173483A1
Title: AGENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH UNDESIRED CELL PROLIFERATION
Abstract: [0001]    The present invention relates to methods for the treatment of from ovarian, lung or colorectal cancer by means of the use of agents capable of inhibiting the expression and/or capable of blocking the activity of leukemia inhibitory factor (LIF). The invention also relates toin vitromethods for designing a customised therapy for a patient suffering from a ovarian, lung or colorectal cancer and for selecting a patient suffering from a ovarian, lung or colorectal cancer to be treated with an agent capable of inhibiting the expression and/or capable of blocking the activity of LIF.
IPC codes: A61K  31/  7088            A I
A61K  39/    00            A I
A61P  35/    00            A I
C07K  16/    22            A I
C07K  16/    24            A I
C12N  15/   113            A I
Claims: number: 1
text: An agent capable of inhibiting the expression and/or capable of blocking the activity of leukemia inhibitory factor (LIF) for use in the treatment of a cancer selected from ovarian cancer, lung cancer and colorectal cancer.
number: 2
text: The agent for use according to claim 1, wherein said cancer ischaracterised by having high LIF levels.
number: 3
text: Anin vitro method for designing a customised therapy for a patient suffering from a cancer selected from ovarian cancer, lung cancer and colorectal cancer, comprising:
number: 4
text: Anin vitro method for selecting a patient suffering from a cancer selected from ovarian cancer, lung cancer and colorectal cancer to be treated with an agent capable of inhibiting the expression and/or capable of blocking the activity of LIF, comprising:
number: 5
text: The method according to any of claims 3 or 4, wherein the sample is a tissue sample or a biofluid.
number: 6
text: The method according to claim 5, wherein the tissue sample is a tumor sample.
number: 7
text: The method according to claim 5, wherein the biofluid is blood, serum or plasma.
number: 8
text: The agent for use according to any of claims 1 or 2, or the method according to any of claims 3 to 7, wherein the levels of LIF are quantified by means of western blotting, immunohistochemistry, immunohistofluorescence, mass spectrometry, mass spectrometry linked to immunoprecipitation or ELISA.
number: 9
text: The agent for use according to claim 8, or the method according to claim 5, wherein the levels of LIF are quantified by means of immunohistochemistry or immunohistofluorescence and are measured as a value of LIF-score or H-score.
number: 10
text: The agent for use according to claim 9, wherein the cancer ischaracterised by having a LIF-score equal to or greater than zero or an H-score equal or greater than zero.
number: 11
text: The method according to claim 10, wherein the reference value is a LIF-score equal or greater than zero or an H-score equal or greater than zero.
number: 12
text: The agent for use according to any of claims 1 or 2, or the method according to any of claims 3 to 9 and 11, wherein the agent capable of inhibiting the expression of LIF is selected from the group consisting of a siRNA specific for LIF, an antisense oligonucleotide specific for LIF and a ribozyme specific for LIF.
number: 13
text: The agent for use according to any of claims 1 or 2, or thein vitro method according to any of claims 3 to 9 and 11, wherein the agent capable of blocking the activity of LIF is selected from the group consisting of an antibody specific for LIF, a polypeptide specific for LIF, an oligonucleotide specific for LIF and an inhibitor of LIF receptor binding specific for LIF.
number: 14
text: The agent for use according to claim 13, or the method according to claim 13, wherein said antibody specific for LIF is a LIF neutralising antibody.
number: 15
text: The agent for use according to any of claims 1 or 2, or the method according to any of claims 3 to 9 and 11 to 14, wherein the lung cancer is non-small cell lung cancer (NSCLC).
Office action: search_report, dated 2017-05-31
Rejection reasons: novelty_epc_54
Prior art cited: ref_id: WO2010115868A2
ref_type: patent
severity: background
ref_id: US6110462A
ref_type: patent
severity: background
ref_id: US5093246A
ref_type: patent
severity: background
ref_id: US5654157A
ref_type: patent
severity: background
ref_id: WO2005030803A1
ref_type: patent
severity: background
ref_id: WO9601319A1
ref_type: patent
severity: background
ref_id: - KAMOHARA ET AL., INT J ONCOL, vol. 30, 2007, pages 977 - 983
ref_type: npl
severity: background
ref_id: - CHENG ET AL., BIOL REPROD, vol. 70, January 2004 (2004-01-01), pages 1270 - 1276
ref_type: npl
severity: background
ref_id: - WHITE ET AL.: "J.Biol.Chem.", PROC. NATL. ACAD. SCI. USA, vol. 104, 2007, pages 19357 - 19362
ref_type: npl
severity: background
ref_id: - BELL ET AL., J. RHEUMATOL., vol. 24, 1997, pages 2394
ref_type: npl
severity: background
ref_id: - KOHLER, MILSTEIN ET AL., NATURE, vol. 256, 1975, pages 495
ref_type: npl
severity: background
ref_id: - KIM ET AL., J. IMMUNOL. METH., vol. 156, 1992, pages 9 - 17
ref_type: npl
severity: background
ref_id: - ALPHONSO ET AL., J. LEUKOCYTE BIOLOGY (ABSTRACTS OF THE 28TH NATIONAL MEETING OF THE SOCIETY FOR LEUKOCYTE BIOLOGY, vol. 0, no. SP.2, 1991, pages 49
ref_type: npl
severity: background
ref_id: - HUDSON ET AL., J .BIOL.CHEM., vol. 271, 1996, pages 11971 - 11978
ref_type: npl
severity: background
ref_id: - FAIRLIE/ W.D. ET AL., J.BIOL.CHEM., vol. 279, 2004, pages 2125 - 2134
ref_type: npl
severity: background
ref_id: - METZ; S. ET AL., J.BIOL.CHEM., vol. 283, 2008, pages 5985 - 5995
ref_type: npl
severity: background
ref_id: - SAMBROOK ET AL.: "Molecular cloning: a Laboratory Manual", vol. 1-3, 2001, COLD SPRING HARBOR LABORATORY PRESS
ref_type: npl
severity: background
ref_id: WO2015040243A2
ref_type: patent
severity: background
ref_id: US2015133376A1
ref_type: patent
severity: background
ref_id: WO2011124566A1
ref_type: patent
severity: background
ref_id: WO2016040657A1
ref_type: patent
severity: background
ref_id: - JUNG EUN SHIN ET AL: "Epigenetic up-regulation of leukemia inhibitory factor (LIF) gene during the progression to breast cancer", MOLECULES AND CELLS, vol. 31, no. 2, 3 December 2010 (2010-12-03), KR, pages 181 - 189, XP055244105, ISSN: 1016-8478, DOI: 10.1007/s10059-011-0020-z
ref_type: npl
severity: background
ref_id: - ESTROV Z ET AL: "LEUKEMIA INHIBITORY FACTOR BINDS TO HUMAN BREAST CANCER CELLS AND STIMULATES THEIR PROLIFERATION", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 15, no. 10, 1 October 1995 (1995-10-01), pages 905 - 913, XP001037939, ISSN: 1079-9907
ref_type: npl
severity: background
ref_id: - KAMOHARA HIDENOBU ET AL: "Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: Involvement of regulation of LIF and its receptor expression", INTERNATIONAL JOURNAL OF ONCOLOGY, DEMETRIOS A. SPANDIDOS ED. & PUB, GR, vol. 30, no. 4, 1 April 2007 (2007-04-01), pages 977 - 983, XP009136730, ISSN: 1019-6439
ref_type: npl
severity: background
ref_id: - LIU J ET AL: "Expression of leukemia-inhibitory factor as an autocrinal growth factor in humanmedulloblastomas", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 125, no. 8-9, 1 August 1999 (1999-08-01), pages 475 - 480, XP002980338, ISSN: 0171-5216, DOI: 10.1007/S004320050304
ref_type: npl
severity: background
ref_id: - WYSOCZYNSKI MARCIN ET AL: "An in vitro and in vivo evidence that downregulation of leukemia inhibitory factor (LIF) receptor (LIF-R) decreases the metastatic potential of human rhabdomyosarcoma (RMS) cells.", BLOOD, vol. 108, no. 11, Part 1, November 2006 (2006-11-01), & 48TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ORLANDO, FL, USA; DECEMBER 09 -12, 2006, pages 724A, XP002756746, ISSN: 0006-4971
ref_type: npl
severity: background
ref_id: - ALBRENGUES J ET AL: "LIF mediates proinvasive activation of stromal fibroblasts in cancer", CELL REPORTS, ELSEVIER INC, US, vol. 7, no. 5, 12 June 2014 (2014-06-12), pages 1664 - 1678, XP002733832, ISSN: 2211-1247, [retrieved on 20140522], DOI: 10.1016/J.CELREP.2014.04.036
ref_type: npl
severity: background
ref_id: - B. W. C. TSE ET AL: "Antibody-based immunotherapy for ovarian cancer: where are we at?", ANNALS OF ONCOLOGY., vol. 25, no. 2, 26 November 2013 (2013-11-26), NL, pages 322 - 331, XP055266783, ISSN: 0923-7534, DOI: 10.1093/annonc/mdt405
ref_type: npl
severity: background
ref_id: - F YE ET AL: "Expression of leukaemia inhibitory factor in epithelial ovarian carcinoma: correlation with clinical characteristics", HISTOPATHOLOGY., vol. 53, no. 2, 1 August 2008 (2008-08-01), GB, pages 224 - 228, XP055266718, ISSN: 0309-0167, DOI: 10.1111/j.1365-2559.2008.03068.x
ref_type: npl
severity: background
ref_id: - XIAOFENG ZHAO ET AL: "Human epithelial ovarian carcinoma cell-derived cytokines cooperatively induce activated CD4 + CD25 - CD45RA + naïve T cells to express forkhead box protein 3 and exhibit suppressive ability in vitro", CANCER SCIENCE, vol. 100, no. 11, 1 November 2009 (2009-11-01), JP, pages 2143 - 2151, XP055266869, ISSN: 1347-9032, DOI: 10.1111/j.1349-7006.2009.01286.x
ref_type: npl
severity: background
ref_id: - E DOROTHÉ ET AL: "Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells", 15 December 2007 (2007-12-15), XP055249144, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/110/13/4319.full.pdf> [retrieved on 20160210], DOI: 10.1182/blood-2007-02-
ref_type: npl
severity: background
ref_id: - Y. CHEN ET AL: "Gprc5a Deletion Enhances the Transformed Phenotype in Normal and Malignant Lung Epithelial Cells by Eliciting Persistent Stat3 Signaling Induced by Autocrine Leukemia Inhibitory Factor", CANCER RESEARCH, vol. 70, no. 21, 19 October 2010 (2010-10-19), US, pages 8917 - 8926, XP055264999, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-10-0518
ref_type: npl
severity: background
ref_id: - FU J ET AL: "Effect of interleukin-6 on the growth of human lung cancer cell line", CHINESE MEDICAL JOURNAL / ZHONGHUA YIXUE ZAZHI YINGWEN BAN, CHINESE MEDICAL ASSOCIATION, BEIJING, CN, vol. 111, no. 3, 1 March 1998 (1998-03-01), pages 265 - 268, XP008182098, ISSN: 0366-6999
ref_type: npl
severity: background
ref_id: - EDWARD B. GARON: "Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer", SEMINARS IN ONCOLOGY, vol. 42, 1 October 2015 (2015-10-01), US, pages S11 - S18, XP055247767, ISSN: 0093-7754, DOI: 10.1053/j.seminoncol.2015.09.019
ref_type: npl
severity: background
ref_id: - BURG C ET AL: "Leukaemia Inhibitory Factor derived from rat colon carcinoma cells increases host susceptibility to tumour growth", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 7, no. 8, 1 November 1995 (1995-11-01), pages 784 - 792, XP002980337, ISSN: 1043-4666, DOI: 10.1006/CYTO.1995.0094
ref_type: npl
severity: background
ref_id: - BRUNO ROSA ET AL: "Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis", ECANCERMEDICALSCIENCE, vol. 9, 15 October 2015 (2015-10-15), XP055315738, ISSN: 1754-6605, DOI: 10.3332/ecancer.2015.582
ref_type: npl
severity: background
ref_id: - HAIYANG YU ET AL: "LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers", NATURE COMMUNICATIONS, vol. 5, 17 October 2014 (2014-10-17), pages 5218, XP055264997, DOI: 10.1038/ncomms6218
ref_type: npl
severity: background
ref_id: - GUIMBAUD ROSINE ET AL: "Leukemia inhibitory factor involvement in human ulcerative colitis and its potential role in malignant course", vol. 9, no. 4, 1 December 1998 (1998-12-01), pages 607 - 612, XP008182109, ISSN: 1148-5493, Retrieved from the Internet <URL:http://www.jle.com/en/revues/ecn/e-docs/leukemia_inhibitory_factor_involvement_in_human_ulcerative_colitis_and_its_potential_role_in_malignant_course._90166/article.phtml>
ref_type: npl
severity: background
ref_id: - DANIELLE N. SETO ET AL: "A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 290, no. 32, 7 August 2015 (2015-08-07), US, pages 19976 - 19986, XP055264989, ISSN: 0021-9258, DOI: 10.1074/jbc.M115.638411
ref_type: npl
severity: background
ref_id: WO2011124566
ref_type: patent
severity: background
ref_id: WO2015040243
ref_type: patent
severity: novelty_destroying
ref_id: US2015133376
ref_type: patent
severity: background
ref_id: WO2016040657
ref_type: patent
severity: novelty_destroying
ref_id: - JUNG EUN SHIN ET AL, "Epigenetic up-regulation of leukemia inhibitory factor (LIF) gene during the progression to breast cancer", MOLECULES AND CELLS, KR, (20101203), vol. 31, no. 2, doi:10.1007/s10059-011-0020-z, ISSN 1016-8478, pages 181 - 189, XP055244105 [A] 1-14
ref_type: npl
severity: background
ref_id: - ESTROV Z ET AL, "LEUKEMIA INHIBITORY FACTOR BINDS TO HUMAN BREAST CANCER CELLS AND STIMULATES THEIR PROLIFERATION", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, MARY ANN LIEBERT, NEW YORK, NY, US, (19951001), vol. 15, no. 10, ISSN 1079-9907, pages 905 - 913, XP001037939 [A] 1-14
ref_type: npl
severity: background
ref_id: - KAMOHARA HIDENOBU ET AL, "Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: Involvement of regulation of LIF and its receptor expression", INTERNATIONAL JOURNAL OF ONCOLOGY, DEMETRIOS A. SPANDIDOS ED. & PUB, GR, (20070401), vol. 30, no. 4, ISSN 1019-6439, pages 977 - 983, XP009136730 [A] 1-14
ref_type: npl
severity: background
ref_id: - LIU J ET AL, "Expression of leukemia-inhibitory factor as an autocrinal growth factor in humanmedulloblastomas", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, (19990801), vol. 125, no. 8-9, doi:10.1007/S004320050304, ISSN 0171-5216, pages 475 - 480, XP002980338 [A] 1-14
ref_type: npl
severity: background
ref_id: - WYSOCZYNSKI MARCIN ET AL, "An in vitro and in vivo evidence that downregulation of leukemia inhibitory factor (LIF) receptor (LIF-R) decreases the metastatic potential of human rhabdomyosarcoma (RMS) cells.", BLOOD, & 48TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ORLANDO, FL, USA; DECEMBER 09 -12, 2006, (200611), vol. 108, no. 11, Part 1, ISSN 0006-4971, page 724A, XP002756746 [A] 1-14
ref_type: npl
severity: background
ref_id: - ALBRENGUES J ET AL, "LIF mediates proinvasive activation of stromal fibroblasts in cancer", CELL REPORTS, ELSEVIER INC, US, vol. 7, no. 5, doi:10.1016/J.CELREP.2014.04.036, ISSN 2211-1247, (20140612), pages 1664 - 1678, (20140522), XP002733832 [A] 1-14
ref_type: npl
severity: background
ref_id: - B. W. C. TSE ET AL, "Antibody-based immunotherapy for ovarian cancer: where are we at?", ANNALS OF ONCOLOGY., NL, (20131126), vol. 25, no. 2, doi:10.1093/annonc/mdt405, ISSN 0923-7534, pages 322 - 331, XP055266783 [A] 12-14
ref_type: npl
severity: background
ref_id: - F YE ET AL, "Expression of leukaemia inhibitory factor in epithelial ovarian carcinoma: correlation with clinical characteristics", HISTOPATHOLOGY., GB, (20080801), vol. 53, no. 2, doi:10.1111/j.1365-2559.2008.03068.x, ISSN 0309-0167, pages 224 - 228, XP055266718 [A] 12-14
ref_type: npl
severity: background
ref_id: - XIAOFENG ZHAO ET AL, "Human epithelial ovarian carcinoma cell-derived cytokines cooperatively induce activated CD4 + CD25 - CD45RA + naïve T cells to express forkhead box protein 3 and exhibit suppressive ability in vitro", CANCER SCIENCE, JP, (20091101), vol. 100, no. 11, doi:10.1111/j.1349-7006.2009.01286.x, ISSN 1347-9032, pages 2143 - 2151, XP055266869 [A] 12-14
ref_type: npl
severity: background
ref_id: - E Dorothé ET AL, "Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells", doi:10.1182/blood-2007-02-, (20071215), URL: http://www.bloodjournal.org/content/110/13/4319.full.pdf, (20160210), XP055249144 [A] 1-14
ref_type: npl
severity: background
ref_id: - Y. CHEN ET AL, "Gprc5a Deletion Enhances the Transformed Phenotype in Normal and Malignant Lung Epithelial Cells by Eliciting Persistent Stat3 Signaling Induced by Autocrine Leukemia Inhibitory Factor", CANCER RESEARCH, US, (20101019), vol. 70, no. 21, doi:10.1158/0008-5472.CAN-10-0518, ISSN 0008-5472, pages 8917 - 8926, XP055264999 [A] 1-15
ref_type: npl
severity: background
ref_id: - FU J ET AL, "Effect of interleukin-6 on the growth of human lung cancer cell line", CHINESE MEDICAL JOURNAL / ZHONGHUA YIXUE ZAZHI YINGWEN BAN, CHINESE MEDICAL ASSOCIATION, BEIJING, CN, (19980301), vol. 111, no. 3, ISSN 0366-6999, pages 265 - 268, XP008182098 [A] 1-15
ref_type: npl
severity: background
ref_id: - EDWARD B. GARON, "Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer", SEMINARS IN ONCOLOGY, US, (20151001), vol. 42, doi:10.1053/j.seminoncol.2015.09.019, ISSN 0093-7754, pages S11 - S18, XP055247767 [A] 1-15
ref_type: npl
severity: background
ref_id: - BURG C ET AL, "Leukaemia Inhibitory Factor derived from rat colon carcinoma cells increases host susceptibility to tumour growth", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, (19951101), vol. 7, no. 8, doi:10.1006/CYTO.1995.0094, ISSN 1043-4666, pages 784 - 792, XP002980337 [X] 1,2,13 * X for Invention 3; page  787  - page  788 * [I] 1-14
ref_type: npl
severity: novelty_destroying
ref_id: - BRUNO ROSA ET AL, "Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis", ECANCERMEDICALSCIENCE, (20151015), vol. 9, doi:10.3332/ecancer.2015.582, ISSN 1754-6605, XP055315738 [A] 1-14
ref_type: npl
severity: background
ref_id: - HAIYANG YU ET AL, "LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers", NATURE COMMUNICATIONS, (20141017), vol. 5, doi:10.1038/ncomms6218, page 5218, XP055264997 [I] 1-14 * X for Invention 3; page  8  - page  10; figure 2f *
ref_type: npl
severity: background
ref_id: - GUIMBAUD ROSINE ET AL, "Leukemia inhibitory factor involvement in human ulcerative colitis and its potential role in malignant course", vol. 9, no. 4, ISSN 1148-5493, (19981201), pages 607 - 612, EUROPEAN CYTOKINE NETWORK, JOHN LIBBEY EUROTEXT LTD, FR, URL: http://www.jle.com/en/revues/ecn/e-docs/leukemia_inhibitory_factor_involvement_in_human_ulcerative_colitis_and_its_potential_role_in_malignant_course._90166/article.phtml, XP008182109 [I] 1-14 * the whole document *
ref_type: npl
severity: background
ref_id: - DANIELLE N. SETO ET AL, "A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia", JOURNAL OF BIOLOGICAL CHEMISTRY, US, (20150807), vol. 290, no. 32, doi:10.1074/jbc.M115.638411, ISSN 0021-9258, pages 19976 - 19986, XP055264989 [I] 1-14 * the whole document *
ref_type: npl
severity: background
Final disposition: pending (2017-05-31)